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Several reports have shown that urotensin 2 (UTS2) and its receptor (UTS2R) are involved in glucose 
metabolism and insulin resistance, which lead to development of type 2 diabetes mellitus (T2DM) in humans. In 
the present study, we annotated both bovine UTS2 and UTS2R genes and identified 5 single nucleotide 
polymorphisms (SNPs) for the former gene and 14 mutations for the latter gene. Four mutations were genotyped 
on a Wagyu x Limousin reference population, including 6 F1 bulls, 113 F1 dams and ~250 F2 progeny. Among 12 
phenotypes related to fat deposition and fatty acid composition, we observed that the UTS2 gene was 
significantly associated with the amount of skeletal saturated fatty acids, while its receptor (UTS2R) gene had 
significant effects on amounts of saturated and monounsaturated fatty acids, Δ9 desaturase activity for 
converting 16:0 into 16:1, muscle fat (marbling) score and Longissimus Dorsi muscle area. However, in this 
population, these markers were not associated with subcutaneous fat depth or percent kidney, pelvic and heart 
fat. We also found that mutations in the promoter regions altered the promoter activities in both genes and 
coding SNPs might affect the mRNA stability in the UTS2R gene. Overall, our present study provides the first 
evidence that both UTS2 and UTS2R genes regulate skeletal muscle fat accumulation and fatty acid metabolism, 
thus indicating their potential pathological functions related to obesity and T2DM in humans. 
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1.  Introduction 
Three members of the urotensin II family of 
peptides have been discovered in mammals, including 
urotensin 2 (UTS2), urotensin 2 receptor (UTS2R) and 
urotensin 2 domain containing (UTS2D). UTS2 is 
cyclic peptide with an 11 amino acid mature peptide 
in human, but it has been recognized as a hormone in 
the neurosecretory system of teleost fish for over 30 
years [1]. In addition, UTS2 is a potent 
vasoconstrictive peptide that regulates both 
endothelium-dependent and independent 
vasodilation [2]. The human orphan G 
protein-coupled receptor 14 (GPR14) was cloned in 
1995 [3] and then confirmed to function as the UTS2 
receptor (UTS2R) [4]. Interestingly, the UTS2R shares 
highest identity with the somatostatin receptor SSTR4 
[3]. A novel urotensin II-related peptide, now named 
the urotensin 2 domain containing (UTS2D) was also 
isolated in human, mouse and rat [5]. UTS2D binds 
and activates the urotensin 2 receptor, suggesting that 
it is the endogenous and functional ligand for UTS2R. 
 
Among these three genes, both UTS2 and UTS2R 
have been reported to affect glucose metabolism and 
insulin resistance, a core pathological characteristic of 
patients with type 2 diabetes mellitus (T2DM). In 
Hong Kong Chinese, the GGT haplotype (-605G, 143G 
and 3836T) in the UTS2 gene is associated with higher 
plasma level of urotensin 2 and insulin, and higher 
homeostasis model assessment of insulin resistance 
index and beta-cell function, while the AC haplotype 
(-11640A and -8515C) in the UTS2R gene has a higher 
amount of plasma glucose 2 h after a 75 g oral glucose 
load [6]. In human diabetic tissue, Langham and 
colleagues [7] found that expression of both UTS2 and 
UTS2R are increased 45- and almost 2,000-fold in 
comparison to control nephrectomy tissue, 
respectively (P<0.0001) using quantitative real-time 
polymerase chain reaction. In the healthy rat, infusion 
of synthetic rat urotensin 2 inhibits both insulin 
release induced by glucose and insulin responses 
induced by carbachol, glucagon-like peptide-1, and a 
calcium channel agonist [8]. However, in 
streptozotocin-induced diabetic rats, long-term Int. J. Biol. Sci. 2008, 4 
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treatment with palosuran, a UTS2R antagonist, 
improved survival, increased insulin, and slowed the 
increase in glycemia, glycosylated hemoglobin, and 
serum lipids [9]. Therefore, the urotensin 2 system 
plays a unique role both in insulin secretion and in the 
renal complications of diabetes.   
Studies have shown that the fat droplets 
accumulated in human skeletal muscle are a major 
contributor to insulin resistance [10]. For example, in 
male Pima Indians, negative relationships were found 
between amounts of triglyceride in skeletal muscle 
and physiological and supraphysiological insulin 
levels, and nonoxidative glucose disposal (r = -0.44 – 
-0.53, P < 0.01) [11]. In a European population, muscle 
lipid was correlated with percent body fat (r = 0.50, p 
= 0.028), waist:hip ratio (r = 0.74, p < 0.001), visceral 
fat (r = 0.62, p = 0.004) and insulin sensitivity (r = 
-0.53, p = 0.016) [12]. Just recently, Suzuki and 
colleagues [13] reported that enhanced muscle mass 
might have positive effects on fat utilization, thus 
reducing the metabolic problems and insulin 
resistance associated with obesity and T2DM. In 
addition, both UTS2 and UTS2R mRNA are expressed 
in skeletal muscle as well as in lung, pancreas, kidney 
and liver [14]. Therefore, the objective of the present 
study was to determine whether both UTS2 and 
UTS2R genes contribute to muscle lipid metabolism 
using cattle as a model organism.   
2.  Materials and Methods 
Animals, body fat deposition and fatty acid 
composition.  
A Wagyu–Limousin F2 reference population was 
used in the present study, including 6 F1 bulls, 113 F1 
dams and ~250 F2 progeny. The entire core of the 
longissimus dorsi was sampled from these F2 progeny 
and relative amounts of saturated (SFA), 
monounsaturated (MUFA) and polyunsaturated fatty 
acids (PUFA), three indexes of Δ9 desaturase activity 
as R1 = (14:1/14:0) x 100%; R2 = (16:1/16:0) x 100% and 
R3  =  (18:1/18:0) x 100%, conjugated linoleic acid 
mg/100 g dry meat (CLA), cholesterol mg/100 g dry 
meat (CHOL), Longissimus Dorsi area (LDA in in2) and 
muscle fat (marbling) score (MFMS) were measured. 
In addition, subcutaneous fat depth (SFD) and percent 
kidney-pelvic-heart fat (KPH) were also recorded in 
the population. Muscle fat (marbling) score was 
determined at the interface of the 12th and 13th ribs 
and was evaluated by subjective comparison of the 
amount of fat within the longissimus muscle with 
photographic standards (National Livestock and Meat 
Board 1981). Subcutaneous fat depth was recorded at 
the 12th rib at a point three-fourths the width of the 
longissimus muscle from its chine bone end. The 
amount of KPH was estimated and recorded as a 
percentage of carcass weight. Development and 
management of the Wagyu–Limousin reference 
population and measurement and definition of these 
phenotypes were described previously [15,16].   
Gene, mutation, genotyping and association.  
Both cDNA and genomic DNA sequences of the 
bovine  UTS2 and UTS2R were retrieved from the 
GenBank databases using a comparative approach, as 
previously described [17]. Alignment between cDNA 
and genomic DNA sequences was used to determine 
genomic organization for each of these two genes. A 
total of 11 pairs of primers (Table 1) were designed 
based on the genomic DNA sequences and used to 
screen genetic polymorphisms in the promoter, coding 
and untranslated regions of both bovine UTS2 and 
UTS2R genes. Approximately 50 ng of genomic DNA 
each from six Wagyu x Limousin F1 bulls was 
amplified in a final volume of 10 μl that contained 12.5 
ng of each primer, 150 μM dNTPs, 1.5 mM MgCl2, 50 
mM KCl, 20 mM Tris-HCl and 0.25U of Platinum Taq 
polymerase (Invitrogen, Carlsbad, CA). The following 
PCR conditions were used: 94oC for 2 min, 35 cycles of 
94oC for 30 sec, 60oC for 30 sec and 72oC for 30 sec, 
followed by a final 5 min extension at 72oC. PCR 
products were then sequenced on ABI 3730 sequencer 
in the Laboratory for Biotechnology and Bioanalysis 
(Washington State University) using a standard 
protocol and polymorphisms were detected.   
A total of 5 mutations were identified in UTS2 
and 14 in UTS2R gene, respectively. Two SNPs (single 
nucleotide polymorphisms), one in the promoter and 
one in intron 2 of UTS2, and two mutations, one 
INDEL (insertion/deletion) in the promoter and one 
coding SNP of UTS2R, were selected for genotyping 
on a Sequenom iPLEX assay using services provided 
by the Children's Hospital Oakland Research Institute, 
Oakland, California. The phenotypic data for all 
measurements described above were analyzed in a 
fixed effects model that included the effects of year, 
gender, age at harvest (linear) and the genotype for 
each marker using the GLM (general linear model) 
procedure of SAS v9.1 (SAS Institute Inc., Gary, NC). 
Pair-wise comparisons of least squares means were 
performed using a protected t-test.   
Promoter activity assay.  
Among the genetic polymorphisms discovered 
above, three SNPs were located in the promoter region 
of UTS2 and one insertion/deletion in the promoter of 
UTS2R gene, respectively. The effects of these 
mutations on promoter activities were then examined 
using a Dual-Luciferase Report Assay System 
(Promega, Madison, WI). The forward and reverse Int. J. Biol. Sci. 2008, 4 
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gene-specific primers that were used to amplify the 
promoter regions (Table 1) were then engineered with 
a 5’ BglII and 3’ HindIII site plus a 5’ tail of CTTC, 
respectively, for directional cloning into the 
BglII/HindI I I  s i t e  o f  p G L 3 - b a s i c  ( P r e m e g a ,  M a d i s o n ,  
WI). Two types of haplotypes at three polymorphic 
sites in the UTS2 promoter: A-C-A and C-A-G; and 
two types of INDELs in the UTS2R promoter: TA 
insertion and TA deletion were prepared for the 
promoter constructs. The human lung carcinoma 
H1299 cells were transfected with each of the 
recombinant pGL3 plasmids containing the constructs 
described above. pRL-CMV plasmid was also 
co-transfected into H1299 cells as a transfection 
control. The human cells were collected 28 hours 
post-transfection and firefly luciferase and Renilla 
luciferase activities were measured with the Dual 
Luciferase Reporter Assay system according to the 
manufacturer’s protocol. Light emission was 
quantified with a Multilabel Counter (Wallace 1420 
Victor 2, Turku, Finland). Triplicate data were 
collected from three independent experiments.  The 
ratios of firefly luciferase activity to Renilla luciferase 
activity were calculated and used to compare the 
differences in activity between two constructs for each 
gene. 
Table 1. Primers designed for mutation detection in the bovine UTS2 and UTS2R genes. 
 
 
3.  Results and Discussion 
Comparative annotation of UTS2 and UTS2R genes.   
The cDNA sequences of human UTS2 
(NM_021995.1, transcript variant 1) and UTS2R 
(NM_018949.1) genes were used as references for 
BLAST searches against GenBank “nr” database, thus 
retrieving orthologous cDNA sequences for both 
bovine genes (CO872879 for UTS2 and 
NM_001040484.1 for UTS2R). BLAST searches using 
the bovine cDNA sequences as queries then obtained 
their genomic DNA sequences (AAFC03010889 for 
UTS2 and AAFC03013715 for UTS2R) from the bovine 
genome sequencing database (Build 3.1).   
For the bovine UTS2 gene, alignment between 
the cDNA and the genomic DNA sequences revealed 
that it consists of four exons only, which correspond to 
the transcript variant 2 of the human ortholog 
(NM_006786) (Figure 1A). However, alignment Int. J. Biol. Sci. 2008, 4 
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between the human transcript variant 1 (NM_021995) 
and the same bovine genomic DNA contig detected a 
relic for exon 1 of the variant, but it seems that its 
expression in cattle is totally destroyed by an unusual 
intron splicing site of CT instead of GT (see 
AAFC03010889.1:g.9800C). In fact, GenBank databases 
show that the UTS2 variant 1 does not exist in either 
mouse (NM_011910) or rat (NM_019160).   
 
Figure 1. Genomic organizations of UTS2 (A) and UTS2R (B) 
between human and cattle. 
 
In mammals, the UTS2R is an intronless gene. 
However, the current GenBank information shows 
that the bovine UTS2R gene contains a 5’UTR of 89 bp 
and a 3’UTR of 384 bp (NM_001040484.1), while the 
human ortholog has none of them (NM_018949.1). 
Therefore, we decided to re-annotate the gene in both 
human and cow using an electronic rapid 
amplification of cDNA ends (e-RACE) approach. 
Basically, we used the genomic DNA sequences 
flanking the coding sequences as queries for BLAST 
searches to determine both 5’UTR and 3’UTR ends of 
the genes against the EST (expressed sequence tag) 
databases. The e-RACE approach retrieved an EST 
BF513269 for the 5’UTR end and AA621666 for the 
3’UTR end of the human UTS2R gene. The same 
approach also obtained an EST EE388038 for the 
5’UTR end and CK775836 for the 3’UTR end of the 
bovine ortholog. As a result, we complied a tentative  
full-length cDNA sequence of 3,288 bp for the human 
gene (see AADD01156981.1 from position 31,842 bp to 
35,129 bp) and 2,911 bp for the bovine gene (see 
AAFC02086367.1 from position 3,482 bp to 6,392 bp). 
The former cDNA sequence has a 5’UTR of 95 bp, a 
coding sequence of 1170 bp and a 3’UTR of 2,023 bp, 
while the latter cDNA sequence contains a 5’UTR of 
1,270 bp, a coding sequence of 1,155 bp and a 3’UTR of 
486 bp (Figure 1B). In addition, a polyadenylation site 
(AAUAAA) was also identified in the newly 
annotated cDNA sequences of both human and 
bovine UTS2R genes. 
Genetic polymorphisms.  
Direct sequencing of PCR products on 6 F1 bulls 
identified three SNPs in the promoter and two SNPs 
in intron 2 of the UTS2 gene: 
AAFC03010889.1:g.9408A>C,  g.9552C>A,  g.9628G>A, 
g.13294G>A and g.13900A>C, respectively. 
Interestingly, we observed in these 6 F1 bulls that three 
promoter SNPs and two intronic SNPs have no 
historical recombination by forming two haplotypes 
(ACA and CAG) in the former region and two 
haplotypes (GA and AC) in the latter region. 
Therefore, only one SNP from the promoter and one 
SNP from the intron 2 were chosen for genotyping.   
For the bovine UTS2R, one insertion/deletion 
(INDEL) with two nucleotides of TA 
(AAFC03013715.1:g.2935-36TA>--) was detected in the 
promoter region, while 13 SNPs were identified in the 
coding and 3’UTR regions of the gene, including 
AAFC03013715.1:c.6446T>C,  c.6506C>T,  c.6593T>C, 
c.6749G>A,  c.6830T>C,  c.6842A>G,  c.7232G>A, 
c.7359C>T,  g.7466G>C,  g.7632A>G,  g.7692C>T, 
g.7714G>A and g.7720G>A, respectively. Although the 
first eight SNPs in the bovine UTS2R gene are coding 
SNPs, none are missense mutations. However, the 
Mfold web server [18] predicted that these 13 SNPs do 
cause mRNA secondary structure changes in the 
bovine gene (Figure 2). In addition to the promoter 
INDEL, only one of these 13 SNPs was chosen for 
genotyping, because they form just two haplotypes as 
described in Figure 2. 
Associations of UTS2 and UTS2R with body fat 
deposition.  
The association analysis involved four mutations, 
i.e., AAFC03010889.1: g.9628G>A and g.13900A>C in 
the bovine UTS2 gene and 
AAFC03013715.1:g.2935-36TA>-- and c.6506C>T in the 
bovine  UTS2R gene, which were genotyped on a 
Sequenom iPLEX assay. As two SNPs in the former 
genes had no combination in these F2 progeny by 
forming two haplotypes AA and CG, only three 
markers were used in the data analysis. The 
phenotypes that had at least one suggestive (P=0.05 – 
0.06) or significant (P<0.05) association are listed in 
Table 2. The UTS2 gene had a significant effect on one 
trait only, i.e., the relative amount of saturated fatty 
acids. In particular, animals with GG genotypes had 
1.39 units (P=0.0365) less SFA than animals with AA 
genotypes. For the bovine UTS2R gene, the promoter 
INDEL polymorphism was significantly associated 
with MUFA (P=0.0452), R2 (P=0.0177) and LDA Int. J. Biol. Sci. 2008, 4 
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(P=0.0488) (Table 2). The homozygous animals with 
the insertion allele (TA/TA) had 1.65 units higher 
MUFA, but 1.70% lower R2 activity and 0.56 in2 
smaller LD muscle area than the homozygous animals 
with TA deleted (Table 2). The coding SNP in the 
bovine UTS2R gene had significant impacts on both 
SFA and MUFA, plus a suggestive effect on MFMS 
(Table 2). The TT animals had an additional 0.64 units 
of muscle fat deposition and 1.82 units of MUFA, but 
1.75 less units of SFA than the CC animals. 
 
Figure 2. The UTS2R mRNA local secondary structures between haplotype TCTGTAGCGACGG and haplotype 
CTCACGATCGTAA based on two-segment analysis (A1 vs. B1 and A2 vs. B2). 
Table 2. Associations of UTS2 and UTS2R genes with muscle fat phenotypes* 
 Int. J. Biol. Sci. 2008, 4 
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Mutations and promoter activities.  
As indicated above, two types of haplotypes at 
three polymorphic sites in the UTS2 promoter: A-C-A 
and C-A-G; and two types of INDELs in the UTS2R 
promoter: TA insertion and TA deletion, were 
prepared for the promoter constructs to investigate 
how these mutations affect promoter activities of these 
two genes. In the UTS2 promoter, the C-A-G construct 
produced less promoter activities than the A-C-A 
construct by 27% in the H1299 cells (P=0.0234) (Figure 
3). In the UTS2R promoter, the deletion allele yielded 
lower promoter activities than the insertion constructs 
by 16% in the same cell lines (P=0.0436) (Figure 3). A 
search for transcription binding sites using 
MatInspector [19] indicated AAFC03010889.1:g.9408A 
in the UTS2 promoter gained a site for FAST-1 SMAD 
interacting proteins, while AAFC03010889.1:g.9408C 
gained a site for neuron-specific-olfactory factor. At 
the g.9552C>A polymorphic site, the former allele had 
a transcription binding site for AP4 and related 
proteins only, while the latter allele possessed one site 
for MAF/AP1 related factors and one site for octamer 
binding protein. There were a total of four binding 
sites for MAF and AP1 related factors, TCF11 
transcription factor, TALE homeodomain class 
recognizing TG motifs and MYT1 C2HC zinc finger 
protein when an A allele is located at position 
AAFC03010889.1:g.9628. When the g.9628A is 
substituted by g.9628G, only one site was created for 
activator/repressor binding to transcription initiation 
site. Overall, the A-C-A haplotype in the UTS2 
promoter had two additional binding sites than the 
C-A-G haplotype. However, the MatInspector 
program failed to detect any gain/loss of transcription 
binding sites for the insertion or deletion allele in the 
promoter of UTS2R g e n e  a l t h o u g h  t h e y  s h o w e d  a  
difference in promoter activities as described above.   
 
 
Figure 3. Affects of mutations on promoter activity in the 
H1299 cells. 
 
In summary, our present study provided 
evidence that both UTS2 and UTS2R genes are 
involved in skeletal muscle fat deposition and fatty 
acid metabolism. Such evidence is supported by the 
fact that none of the mutations genotyped in the 
population were associated with either subcutaneous 
fat depth (P=0.2074 – 0.9847) or the fat percentage 
surrounding the kidney, pelvic and heart fat (P=0.3278 
– 0.7059) (data not shown). Instead, the UTS2 gene 
was significantly associated with relative amount of 
saturated fatty acids, while its receptor had significant 
effects on relative amounts of saturated and 
monounsaturated fatty acids, Δ9 desaturase activity 
for converting 16:0 into 16:1, overall fat deposition in 
muscle and LD muscle area (Table 2). Although 
mutations in the promoter regions altered the 
promoter activities in both genes (Figure 3) and 
coding SNPs might affect the mRNA stability in 
UTS2R gene (Figure 2), how these genes regulate fat 
deposition and fatty acid composition in skeletal 
muscle remains unknown. 
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